Market Reports

Reading and understanding vendor-supplied tablet drawings

Understanding the tablet drawings supplied by tooling vendors is a meaningful way to learn more about your product, reports John Norman, Technical Service Representative, Natoli Engineering Company

Lessons from a modern-day pandemic: redesigning the pharmaceutical supply chain

The pharmaceutical industry has responded extremely well to the coronavirus pandemic. At the same time, the industry is changing before our eyes. To put it in simple terms, there will be no more “business-as-usual” in pharmaceutical manufacturing after COVID-19, explains Andrew Badrot, CEO, C2 PHARMA

A pivotal time for pharma's global biotechnology industry

In these uncertain times, GEA, the globally active mechanical and plant engineering company, is taking its role in the fight against the coronavirus — and any other — epidemic, extremely seriously. Committed to “Engineering for a better world,” GEA designs and builds modular plant and fully integrated systems help to bring new treatments to market in the shortest possible time

Accelerating vaccine development with AI

Despite the tremendous advances in medical science in recent decades, there is still so much about the human body that we’re yet to discover, reports Billy Sisk, Life Sciences Industry Manager, EMEA, Rockwell Automation

How to comply with FDA-imposed nitrosamine impurity testing

The detection of nitrosamine impurities in commercially available drugs has recently prompted the US FDA to issue multiple product recalls and mandate additional testing to safeguard consumer health and safety; Michael Walker, Technical Expert at Intertek Pharmaceutical Services, and Jon Bardsley, Vertical Marketing Specialist, Pharma and BioPharma, Thermo Fisher Scientific, report

Excipient innovation for enhanced patient compliance: part II

Formulation can be challenging, particularly when working with excipients such as sugar alcohols. However, a new line extension from SPI Pharma offers a solution that leverages the patient-centric benefits of mannitol while avoiding common drug development problems and simplifying manufacturing

Future-proof DMPK studies for next-generation therapeutics

SCIEX's Lei Xiong, Rolf Kern and Elliott Jones explain the top five reasons why you can’t count on ligand-binding assays to study the drug metabolism and pharmacokinetics of biologics

Tackling coronavirus with AI-derived combination drug products: Part I

The ongoing spread of COVID-19 is risking the lives of millions of rare disease patients around the world. Dr David Brown, Chairman and cofounder of Healx, believes the company’s data-driven AI platform is perfectly positioned to support the efforts to find effective treatments and, within weeks, predict which known drugs can be repurposed to treat other conditions

New date announced for Manufacturing Chemist Live

The inaugural conference will now take place on 28-29 October 2020

Excipient innovation for enhanced patient compliance: part I

Formulation can be challenging, particularly when working with excipients such as sugar alcohols. However, a new line extension from SPI Pharma offers a solution that leverages the patient-centric benefits of mannitol while avoiding common drug development problems and simplifying manufacturing

Sustainability and innovation in the complex combination therapy sector

The patient and commercial benefits of bringing new drugs to market in the shortest possible time are well recognised; potential methodologies to reduce the development cycle and accelerate drug product approvals are constantly being explored. As a result, other targets, including the environmental efficacy of a therapy, have traditionally been a distant, secondary objective. Bespak's Jay Bhogaita, Business Director, reports

Delivering certainty in uncertain times

Contract manufacturing organisations (CMOs) in the pharmaceutical sector operate at the sharp end of an industry in which one mistake or delay could be serious or even fatal. Rodney Steel, CEO of the British Contract Manufacturers and Packers Association (BCMPA), discovers how CMOs have become experts in predicting the future, ensuring that nothing is left to chance

Service in times of bits and bytes

Whoever talks to the service experts at Syntegon Technology, formerly Bosch Packaging Technology, communicates both digitally and globally. The shift from analogue to bits and bytes has not only changed communication between service employees and customers. In the course of digitisation, the company has modernised and expanded its entire service portfolio — and has reinvented itself to a certain extent

How AI will disrupt drug development

In the last 4–6 years, companies have been experimenting with new approaches that utilise the latest in artificial intelligence (AI) and machine learning technologies to identify new molecules and validate new drugs faster and more efficiently. Egor Kobelev, VP of Healthcare and Life Sciences at DataArt, examines some of the ways these breakthroughs are transforming drug discovery

Opening the aperture: taking a wider view of the inhalables market

With a new company strategy in place and a combined focus on both drug and device development, Dr Kevin Robinson spoke to Vectura’s new CEO and Executive Director, Will Downie, about the current and future market for inhaled therapies

Rethinking HPLC degassing with novel flat film technology

During the first three decades of liquid chromatography (LC) use, outgassing in the mobile phase was a key challenge in routine LC workflows. However, since the emergence of online degassers in the 1970s, these devices have become an ordinary component of most LC systems and, therefore, their development is often overlooked

Expanding globally: building on a European presence

To build the overseas presence of Federal Equipment Company and solidify our status as a global provider of equipment solutions, we have opened an office in the Netherlands, reports Paul Sombekke, European Business Development Manager

Granulation: an established technology in a changing world

Optimising the granulation process — the most important unit operation during the production of pharmaceutical oral solid dosage forms — is not only a critical aspect of operational excellence, it also plays a major role in preventing downstream compression problems

John Baker: life sciences need to address the reproducibility crisis

The head of product innovation at Abcam says it is crucial that the whole industry finds ways to de-risk the route to the patient as early as possible

Optimise desiccants with 3D validation software

Baltimore's CFD model brings predictive science to validation. Desiccants are tested for performance over time, bringing cost-efficiency to the forefront. Dr Mark Valentine explains

IntelGenx: oral films are drug development’s patent trick

Exploiting improvements in bioavailability, the Canadian company has developed unique oral film technology to help drugmakers secure exclusivity and financial returns

How to avoid sticking and picking in the tableting industry

John Norman and Kevin Queensen of Natoli Engineering explain

Super early bird tickets now on sale for Manufacturing Chemist Live 2020

Manufacturing Chemist Live will provide guidelines and regulations for delegates seeking solutions to optimise pharmaceutical production and safety in the manufacturing environment

Distributed control system reduces downtime for pharmaceutical manufacturer

In this case study, Rockwell Automation describes how Mallinckrodt Pharmaceuticals was able to streamline production and pinpoint potential bottlenecks by implementing a virtualised control system architecture

Trending Articles

  1. You need to be a subscriber to read this article.
    Click here to find out more.
    How CRDMOs are shaping the next generation of antibody-drug conjugates To explore how CRDMOs are leading innovation in ADC development, Dr Kevin Robinson spoke with Srivats Rajagopal, Senior Director, Cell and Protein Sciences, Biology Solutions at Aragen Life Sciences, about key technological advancements and evolving partnership models that are redefining what it means to outsource in this space
  2. NICE recommends enfortumab vedotin with KEYTRUDA for adults in England/Wales with untreated metastatic urothelial cancer The results from the Phase III study EV-302/KN-A39 showed nearly a doubling of survival rates in patients compared with those who received platinum-based chemotherapy, which is the current standard of care in the UK
  3. You need to be a subscriber to read this article.
    Click here to find out more.
    Start with the end in mind: the role of materials control in early CMC strategy for cell therapies Cell and gene therapy products are complex in their design, nature and mode of action. Because of this, the road to market can be a challenging one; littered with variables and failures, what might have been a valuable treatment often fails to reach much-in-need patients
  4. Freeze drying ADCs: points to consider for industrial applications As antibody-drug conjugates gain momentum in the pharmaceutical industry, manufacturers are increasingly looking to implement safe and effective process trains to produce them. Lyophilisation experts at GEA Pharma & Healthcare assess some of the most critical challenges and how to overcome them
  5. Rare diseases: understanding the patient journey In the shadow of Rare Disease Day on 28 February 2019, Dr Kevin Robinson met with Zizi Imatorbhebhe, Senior Director of Strategic Development and Head of PAREXEL’s Rare Disease Center of Excellence (RDCE), to discuss the future of rare disease research

Upcoming event

Enhancing probiotic stability through smarter formulation and packaging strategies

18 September 2025 | Virtual See all